Teriparatide

Parathyroid Hormone AnalogRx: PrescriptionCompound: Approved

Also known as: Bonsity, Forsteo, Forteo, LY333334, Movymia, rhPTH(1-34), Teriparatide acetate, TPD

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Source Teriparatide at Peptiology

Save 10% with code PEPTI-BOSSRABBIT-10

Shop Now & Save 10% →

Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.

Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.

Summary

Teriparatide is a recombinant fragment of human parathyroid hormone (PTH 1-34) administered by daily subcutaneous injection to treat postmenopausal osteoporosis. It stimulates new bone formation, raising bone‑mineral density (BMD) at the spine and hip and lowering the risk of vertebral fractures, especially in patients who have not previously used bisphosphonates.

Mechanism of Action

Teriparatide binds to the type‑1 parathyroid hormone receptor (PTH1R) on osteoblasts and their precursors, activating cyclic AMP and protein kinase pathways that increase osteoblast proliferation, differentiation, and activity. Intermittent exposure favours bone formation over resorption, leading to net gains in trabecular and cortical bone mass.

What the Research Shows

Randomised trials (DATA and DATA‑Switch) showed that teriparatide alone raises lumbar spine BMD by ~6% in 12 months, and that combining it with denosumab yields greater gains (≈9% spine, 4% hip). A 2024 meta‑analysis of 23 head‑to‑head RCTs found teriparatide superior to bisphosphonates in reducing fractures (RR 0.61) and in improving BMD at lumbar spine, femoral neck and total hip. Network meta‑analyses confirm vertebral fracture reduction but note higher rates of withdrawals due to adverse events. Evidence beyond two years and in men or diverse ethnic groups remains limited.

Reported Benefits

Clinical data demonstrate that teriparatide increases BMD at key skeletal sites more than bisphosphonates and, when paired with denosumab, produces additive gains. It lowers vertebral fracture risk, with a pooled risk ratio of 0.61 versus bisphosphonates. The drug is effective in patients naïve to bisphosphonate therapy and can maintain BMD improvements when switched to denosumab after 24 months.

Limitations of the Evidence

Most trials are limited to 12–24 months and focus on postmenopausal women; long‑term durability and safety beyond this period are uncertain. Direct comparisons with newer agents (e.g., romosozumab) are sparse. The combination with denosumab, while promising, is not an approved regimen. Evidence in men, younger adults, and non‑White populations is scarce, and the meta‑analysis notes increased withdrawals due to adverse events.

Safety Considerations

Teriparatide is associated with dose‑related hypercalcaemia; a head‑to‑head trial reported a 6.4% incidence versus 3.4% with abaloparatide. One case of nephrolithiasis possibly linked to therapy was observed in a switch study. Overall adverse‑event rates are comparable to bisphosphonates, but withdrawals due to side effects are higher. Caution is advised in patients with hypercalcaemia, renal stones, or severe renal impairment.

How It Is Administered

Teriparatide is supplied as a sterile solution for subcutaneous injection, typically 20 µg daily. It is administered in the abdomen or thigh using a prefilled pen or syringe. The drug requires refrigeration before use and should be discarded after a single‑use period as indicated by the manufacturer.

Routes of Administration

Subcutaneous

Goals & Uses

  • Treatment of male osteoporosisBone HealthModerate
  • Treatment of glucocorticoid-induced osteoporosisBone HealthHigh
  • Osteoporosis treatmentBone MetabolismHigh
  • Increase in bone mineral densityBone HealthHigh
  • Reduction of vertebral fracture riskBone HealthHigh
  • Increase BMDBone HealthHigh
  • Reduction of nonvertebral fracture riskBone HealthHigh
  • Fracture healingBone RepairLow

Contraindications

  • Prior skeletal radiation therapyOncologyModerate
  • Bone metastasesOncologyHigh
  • Prior radiation therapy involving the skeletonOncologicHigh
  • HypercalcemiaMetabolic DisorderHigh
  • Severe renal impairmentOrganModerateKidney function concerns
  • Pediatric patients with open epiphysesPediatricHigh
  • Paget's disease of boneBone DisorderHigh
  • Osteosarcoma or prior skeletal malignancyOncologicHigh
  • Paget disease of boneSkeletalModerate

Adverse Effects

  • Dizziness/orthostatic hypotensionCardiovascularCommon
  • HypercalcemiaMetabolicUncommon
  • Injection site reactionsLocalCommon
  • HypercalciuriaMetabolicCommon
  • NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
  • Leg crampsMusculoskeletalCommon
  • DizzinessNeurologicCommonFeeling faint, lightheaded, or unsteady

Drug Interactions

  • Loop diureticsModerate
  • Calcium/vitamin D supplementsModerate
  • BisphosphonatesLow
  • DigoxinHigh
  • Calcium supplements and vitamin DLow
  • Antiresorptive agents (bisphosphonates)Moderate
  • Thiazide diureticsModerate

Population Constraints

  • PregnancyReproductive SafetyAbsolute
  • Patients with prior osteosarcomaOncologicAbsolute
  • Pediatric patientsAgeAbsolute
  • Patients with active urolithiasisUrologicRelative
  • Pregnant womenReproductiveAbsolute
  • Severe renal impairment (CrCl <30 mL/min)Organ ImpairmentRelative
  • Children <18 yearsAgeRelative

Regulatory Status

  • European UnionApprovedApproved: severe osteoporosisSame duration limit
  • United StatesApprovedApproved: postmenopausal osteoporosis, male osteoporosisLimited to 2 years of cumulative use
  • United KingdomApprovedApproved: osteoporosis

FDA approved 2002 (brand Forteo); EMA approved for severe osteoporosis; marketed as teriparatide acetate.

Evidence & Sources

Frequently Asked Questions

Who is eligible to receive teriparatide?

Teriparatide is approved for postmenopausal women with osteoporosis who are at high fracture risk, especially those who have not responded adequately to or cannot tolerate other osteoporosis agents.

How does teriparatide differ from bisphosphonates?

Bisphosphonates inhibit bone resorption, whereas teriparatide stimulates new bone formation by activating the PTH1 receptor, leading to increases in both trabecular and cortical bone density.

What are the main safety concerns?

The principal risks are transient hypercalcaemia, possible kidney stone formation, and higher rates of treatment‑related withdrawals. Patients should be monitored for serum calcium and advised to stay well hydrated.

Can teriparatide be used together with denosumab?

A 12‑month trial showed that the combination produced greater BMD gains than either drug alone, but this regimen is not currently approved and should only be considered in research settings.

How long should treatment be continued?

Approved courses are limited to 24 months because long‑term safety data are limited; after this period clinicians typically transition patients to anti‑resorptive therapy to preserve gains.

What is Teriparatide?

Teriparatide is a recombinant fragment of human parathyroid hormone (PTH 1-34) administered by daily subcutaneous injection to treat postmenopausal osteoporosis. It stimulates new bone formation, raising bone‑mineral density (BMD) at the spine and hip and lowering the risk of vertebral fractures, especially in patients who have not previously used bisphosphonates.

What is Teriparatide used for?

Teriparatide is educationally associated with: Treatment of male osteoporosis, Treatment of glucocorticoid-induced osteoporosis, Osteoporosis treatment, Increase in bone mineral density, Reduction of vertebral fracture risk, Increase BMD, Reduction of nonvertebral fracture risk, Fracture healing. Educational only — not medical advice.

How is Teriparatide administered?

Recorded routes of administration: Subcutaneous.

What are the potential side effects of Teriparatide?

Reported adverse effects include: Dizziness/orthostatic hypotension, Hypercalcemia, Injection site reactions, Hypercalciuria, Nausea, Leg cramps, Dizziness. This list is not exhaustive — consult a qualified clinician.

Who should avoid Teriparatide?

Recorded contraindications: Prior skeletal radiation therapy, Bone metastases, Prior radiation therapy involving the skeleton, Hypercalcemia, Severe renal impairment, Pediatric patients with open epiphyses, Paget's disease of bone, Osteosarcoma or prior skeletal malignancy, Paget disease of bone. Consult a qualified clinician before use.

More Parathyroid Hormone Analogues

See all Parathyroid Hormone Analogues →

Browse All PeptidesBuild My Stack